18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation.
Felix G GassertJohannes RübenthalerClemens C CyranJohann S RinkVincent SchwarzeJohanna LuitjensFlorian T GassertMarcus R MakowskiStefan O SchoenbergMarius E MayerhoeferDietmar TamandlMatthias Frank FroelichPublished in: European journal of nuclear medicine and molecular imaging (2021)
Based on the results of the analysis, use of whole-body 18F FDG PET/MRI was identified as a feasible diagnostic strategy for initial staging of rectal cancer from a cost-effectiveness perspective.